These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18697252)

  • 61. [A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
    Arushanian EB
    Eksp Klin Farmakol; 2010 Mar; 73(3):35-9. PubMed ID: 20408429
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Impairment of learning and memory after photothrombosis of the prefrontal cortex in rat brain: effects of Noopept.
    Romanova GA; Shakova FM; Gudasheva TA; Ostrovskaya RU
    Bull Exp Biol Med; 2002 Dec; 134(6):528-30. PubMed ID: 12660828
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.
    Tenovuo O
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):61-7. PubMed ID: 15610946
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Nootropic agents in the complex treatment of patients with traumatic epilepsy].
    Lekomtsev VT
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(6):68-72. PubMed ID: 2171277
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [A neuroprotective effect of the herbal drug neurofit in alcoholic intoxication].
    Dashinamzhilov ZhB; Lonshakova KS; Ubasheev IO; Nikolaev SM; Gulevich AA
    Patol Fiziol Eksp Ter; 2007; (4):27-9. PubMed ID: 18154085
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Pathophysiological rationale for the use of piracetam in sudden deafness].
    García Callejo FJ; Velert Vila MM; Morant Ventura A; Orts Alborch MH; Marco Algarra J; Blay Galaud L
    Acta Otorrinolaringol Esp; 2000 May; 51(4):319-26. PubMed ID: 10984955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.
    Alvarez XA; Sampedro C; Pérez P; Laredo M; Couceiro V; Hernández A; Figueroa J; Varela M; Arias D; Corzo L; Zas R; Lombardi V; Fernández-Novoa L; Pichel V; Cacabelos R; Windisch M; Aleixandre M; Moessler H
    Int Clin Psychopharmacol; 2003 Sep; 18(5):271-8. PubMed ID: 12920387
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmaceutical treatment of cognitive disorders in Alzheimer's disease.
    Senin U; Cherubini A; Palumbo B; Mecocci P
    Funct Neurol; 1997; 12(3-4):211-2. PubMed ID: 9218980
    [No Abstract]   [Full Text] [Related]  

  • 69. Piracetam--an old drug with novel properties?
    Winnicka K; Tomasiak M; Bielawska A
    Acta Pol Pharm; 2005; 62(5):405-9. PubMed ID: 16459490
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Piracetam: a review of pharmacological properties and clinical uses.
    Winblad B
    CNS Drug Rev; 2005; 11(2):169-82. PubMed ID: 16007238
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
    Parnetti L; Mignini F; Tomassoni D; Traini E; Amenta F
    J Neurol Sci; 2007 Jun; 257(1-2):264-9. PubMed ID: 17331541
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [A case of pseudotumorous course of brain demyelinating disease].
    Kislitsyn IuV; Cheremisinov OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(3):61-3. PubMed ID: 15822744
    [No Abstract]   [Full Text] [Related]  

  • 73. [Sudden hearing loss. Treatment with piracetam].
    Solanellas Soler J; Esteban Ortega F; Soldado Patiño L; Jiménez Morales JM
    Acta Otorrinolaringol Esp; 1997; 48(1):21-5. PubMed ID: 9131921
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Experience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disorders.
    Batysheva TT; Bagir' LV; Kostenko EV; Artemova IY; Vdovichenko TV; Ganzhula PA; Zhuravleva EY; Ismailov AM; Lisenker LN; Nesterova OV; Otcheskaya OV; Rotor LD; Khozova AA; Boiko AN
    Neurosci Behav Physiol; 2009 Feb; 39(2):193-7. PubMed ID: 19140003
    [No Abstract]   [Full Text] [Related]  

  • 75. [Comparative evaluation of the neuroprotective activity of phenotropil and piracetam in laboratory animals with experimental cerebral ischemia].
    Tiurenkov IN; Bagmetov MN; Epishina VV
    Eksp Klin Farmakol; 2007; 70(2):24-9. PubMed ID: 17523446
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Salvage of an ischemic toe with piracetam.
    Demirtas Y; Ayhan S; Basterzi Y; Eryilmaz T
    Plast Reconstr Surg; 2005 Jul; 116(1):351-2. PubMed ID: 15988307
    [No Abstract]   [Full Text] [Related]  

  • 77. The effectiveness of piracetam in vertigo.
    Oosterveld WJ
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():54-60. PubMed ID: 10338110
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion].
    Horváth S
    Orv Hetil; 2001 Feb; 142(8):383-9. PubMed ID: 11263076
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Effect of the novel dipeptide nootropic agent noopept and its metabolite cyclo-L-prolylglycine on the transcallosal evoked potential in the rat brain].
    Molodavkin GM; Borlikova GG; Voronina TA; Gudasheva TA; Ostrovskaia RU; Tushmalova NA; Seredenin SB
    Eksp Klin Farmakol; 2002; 65(2):3-5. PubMed ID: 12109288
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MANAGEMENT OF AMNESTIC AND BEHAVIORAL DISORDERS AFTER KETAMINE ANESTHESIA.
    Belenichev I; Burlaka B; Puzyrenko A; Ryzhenko O; Kurochkin M; Yusuf J
    Georgian Med News; 2019 Sep; (294):141-145. PubMed ID: 31687967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.